A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma.
Chunhui ZhouYan LiJiaping LiBotian SongHanfeng LiBin LiangShanzhi GuHaiping LiChangyong ChenSai LiChangli PengFei LiuJuxiong XiaoXue-Ying LongPing LiZhengping XiongXiaoping YiWei-Hua LiaoLiangrong ShiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In patients with previously treated unresectable HCC, subtotal ablation plus toripalimab improved the clinical efficacy as compared with toripalimab alone with an acceptable safety profile.